Skip to content

Amniotic Membrane as an Adjunct Treatment for Hallux Rigidus

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01825356
Enrollment
60
Registered
2013-04-05
Start date
2013-04-08
Completion date
2020-11-10
Last updated
2023-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hallux Rigidus

Brief summary

The purpose of this study is to determine whether patients undergoing a dorsal cheilectomy procedure with implementation of amniotic membrane tissue results in improved clinical and functional outcomes compared to a standard dorsal cheilectomy procedure. Specific Aim 1: To compare American Orthopedic Foot and Ankle Society (AOFAS) scores between patients undergoing dorsal cheilectomy to patients undergoing dorsal cheilectomy with implantation of amniotic membrane tissue. Hypothesis 1: Clinical and functional outcomes, as measured by the AOFAS , in the patients undergoing dorsal cheilectomy with implantation of amniotic membrane tissue will be superior to those without. Specific Aim 2: To compare range of motion between patients undergoing dorsal cheilectomy to patients undergoing dorsal cheilectomy with implantation of amniotic membrane tissue. Hypothesis 2: Patient to undergo dorsal cheilectomy and implantation of amniotic membrane tissue will demonstrate less postoperative stiffness as measured from the pre-and postoperative radiographs. Specific Aim 3: To compare Foot Function Index (FFI) scores between patients undergoing dorsal cheilectomy to patients undergoing dorsal cheilectomy with implantation of amniotic membrane tissue. Hypothesis 3: Clinical and functional outcomes, as measured by the FFI, the patients undergoing dorsal cheilectomy with implantation of amniotic membrane tissue will be superior to those without.

Interventions

PROCEDUREDorsal Cheilectomy without Amniotic Membrane Tissue Implantation
PROCEDUREDorsal Cheilectomy with Amniotic Membrane Tissue Implantation

Sponsors

OrthoCarolina Research Institute, Inc.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients presented with an isolated diagnosis of type II hallux rigidus who are candidates for operative management with dorsal cheilectomy. * Patients over the age of 18 able to consent to participate * The subject is psychosocially, mentally, and physically able to understand and comply with the requirements of the study

Exclusion criteria

* \< 18 years of age * Patients that use ambulatory assistive devices * Patients with systemic inflammtory arthritis * Patient undergoing revision surgery for hallux rigidus to the ipsilateral extremity * Patients with significant arthritis requiring alternative surgery other than dorsal cheilectomy

Design outcomes

Primary

MeasureTime frame
American Orthopedic Foot and Ankle Society (AOFAS) score6 Months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026